Garry Nicholson currently serves as chairman of the board of directors for G1 Therapeutics and as a board member for Tmunity Therapeutics and NextCure. He also previously served on the board of directors for Turning Point Therapeutics, Five Prime Therapeutics and TESARO prior to their acquisitions by large pharmaceutical companies. As former president of Pfizer Oncology, his responsibilities included global commercialization, sales, clinical development, regulatory strategy and business development for Pfizer’s oncology portfolio. Earlier in his career, Mr. Nicholson held various leadership positions in the oncology division of Eli Lilly and Company, including global oncology platform leader. He has also served as president and CEO of XTuit Pharmaceuticals. Mr. Nicholson earned a B.S. in Pharmacy from the University of North Carolina at Chapel Hill and an M.B.A. from the University of South Carolina.

Julie Grant is a General Partner at Canaan, a tech and healthcare venture capital fund with $5B assets under management. She primarily leads investments and company formation efforts in biopharmaceuticals. Julie is a co-founder at Day One, was previously CEO, and is chair of the board. Since joining Canaan in 2013, Julie has incubated, financed, and supported investments in multiple new ventures including Nocion, Synthekine, Protagonist (PTGX), Cellular Research (Acquired by Becton Dickinson), Dermira (DERM), Labrys Biologics, CytomX (CTMX), Unchained Labs, Chrono Therapeutics, Genome Medical, Glooko, Vineti, and Truveris. Prior to joining Canaan, Julie worked at Genentech in multiple capacities across development and commercial. She earned a BS in Molecular Biophysics and Chemistry from Yale, an MPhil BioScience Enterprise from Cambridge, and MBA from Stanford.

Natalie currently serves as Chief Executive Officer (CEO) of Third Harmonic Bio. She has more than 20 years of executive leadership, business development, corporate strategy, and commercial experience gained in a range of therapeutic areas. Prior to Third Harmonic, Natalie served as President and CEO of Audentes, an Astellas company. She joined the company as Senior Vice President and Chief Operating Officer in August 2015 and was subsequently promoted to President and Chief Operating Officer in May 2018, and then to President and CEO in January 2020. Prior to joining Audentes, Natalie served as Senior Vice President, Corporate Development at Hyperion Therapeutics, Inc. (acquired by Horizon Pharma in 2015). Before that, she provided executive-level strategy and business development advisory services to a number of privately-held biopharmaceutical companies. Earlier in her career, Natalie served as Vice President, Business Development at KAI Pharmaceuticals, Inc. (acquired by Amgen in 2012) and held corporate development and commercial roles at InterMune, Inc. (acquired by Roche in 2014) and Genentech, Inc. Natalie holds an M.A. in molecular, cellular and developmental biology from the University of Colorado, Boulder, where she was a Howard Hughes Medical Institute predoctoral fellow, and an A.B. in human biology from Stanford University.

Dan Becker is a Partner at Access Biotechnology, the biopharmaceutical investing arm of Access Industries, a privately held US-based industrial group with global strategic investments of $25+ billion. Prior to joining Access, Dan was a Principal at New Leaf Venture Partners, where he played a key role in multiple private and public biopharma investments, and a Principal in the Health Care practice at the Boston Consulting Group, where he led projects across the healthcare sector with an emphasis on biopharma R&D. Dan trained clinically in internal medicine and nephrology at Brigham and Women’s Hospital and Massachusetts General Hospital, and was a Research Fellow at Harvard Medical School. He obtained both his MD and PhD (Cellular and Molecular Biology) degrees from the University of Michigan, and received his BS in Physiology from the University of Illinois at Urbana-Champaign.

Jeremy Bender, Ph.D., M.B.A. has served as our Chief Executive Officer, President and a member of our board of directors since September 2020. Prior to joining Day One, Dr. Bender was Vice President of Corporate Development at Gilead Sciences, a pharmaceutical company, from March 2018 to September 2020. Prior to that, he was Chief Operating Officer of Tizona Therapeutics from July 2015 to March 2018 and Chief Business Officer of Sutro Biopharma, a biotechnology company specializing in cancer and autoimmune therapeutics, from October 2012 to July 2015. Prior to joining Sutro Biopharma, he was Vice President of Corporate Development at Allos Therapeutics, a biotechnology company focused on cancer treatments, from January 2006 to September 2012. Dr. Bender began his career in the life sciences practice at Boston Consulting Group, a management consulting company. Dr. Bender also sits on the board of Mereo BioPharma as an independent board member. Dr. Bender holds a B.S. in Biological Sciences from Stanford University, a Ph.D. in Microbiology and Immunology from the University of Colorado, and an M.B.A. from the MIT Sloan School of Management.

Scott Garland is the chief executive officer of PACT Pharma, an immuno-oncology company focused on developing neoantigen targeted T-cell therapies for solid tumors. Prior to PACT, Mr. Garland served as president and chief executive officer of Portola Pharmaceuticals, where he led the company through the commercial launch of Andexxa® and a successful acquisition by Alexion. Before joining Portola, Mr. Garland was at Relypsa, where he served as chief commercial officer, and then as president of the U.S. organization after Relypsa’s acquisition by Vifor Pharma. Prior to Relypsa, Mr. Garland was chief commercial officer at Exelixis where he led the launch of cabozantinib. Mr. Garland has held numerous other commercial leadership roles at Genentech, Amgen and Merck, including leading the commercial franchises for two multi-billion dollar therapies – Avastin® and Rituxan®. He also serves as a board member for Calithera Biosciences. Mr. Garland received a Bachelor of Science degree from California Polytechnic State University-San Luis Obispo and a master’s degree in Business Administration from the Fuqua School of Business at Duke University.

Michael Gladstone is a Partner at Atlas Venture, where he builds new therapeutics companies, primarily in the areas of oncology and immunology. Michael contributed to launching several Atlas-originated companies, including Padlock Therapeutics (acquired by BMS), Surface Oncology (NASDAQ: SURF), and IFM Therapeutics Inc (acquired by BMS; and its spinout IFM Tre acquired by Novartis). He has served as a board member or observer for IFM Therapeutics LLC, Indalo Therapeutics, Akrevia Therapeutics, AvroBio (NASDAQ: AVRO), Akero (NASDAQ: AKRO), Delinia (acquired by Celgene), and Replimune (NASDAQ: REPL). Prior to joining Atlas in 2012, Michael worked at L.E.K. Consulting and previously, he conducted HIV vaccine research in the Viral Pathogenesis department of Beth Israel Deaconess Medical Center. Michael serves as an advisor to several organizations, including as member of the Corporate Advisory Committee for National Tay Sachs and Allied Diseases, a national organization focused on funding research, promoting awareness, and supporting families affected by Tay-Sachs and related genetic diseases.

John Josey is a Venture Partner at The Column Group. Previously he served as the President, Chief Executive Officer and a member of the Board of Directors of Peloton Therapeutics, Inc., from 2013 until its acquisition by Merck in 2019. He joined Peloton in 2011 as the first employee in the role of President and Chief Scientific Officer. For over thirteen years, Dr. Josey was employed at Array BioPharma Inc., a company that he helped to build as a member of the founding management team. There he rose to Vice President of Discovery Chemistry. Dr. Josey’s previous experience also includes Amgen, Inc. and the Glaxo Research Institute. He received a BS degree in chemistry from Colorado State University, a PhD in organic chemistry from The University of Texas at Austin, and an MBA from the University of Colorado. He was a Damon Runyon-Walter Winchell Postdoctoral Fellow at the California Institute of Technology. Dr. Josey is currently an adjunct faculty member of the Department of Biochemistry at The University of Texas Southwestern Medical Center. John currently serves on the Board of Directors for VHL Alliance, Circle Pharma, Inc. (Chair), Nura Bio, and Day One Biopharmaceuticals.

Ms. Ramasastry is the managing partner of Life Sciences Advisory, LLC, an independent firm that she founded to provide strategic advice and business development solutions for life science companies. Prior to founding Life Sciences Advisory, Ms. Ramasastry spent 10 years as an investment banker with Merrill Lynch & Company, where she helped establish the biotechnology practice and advised on mergers and acquisitions, and strategic and capital markets transactions. Previously, she served as a financial analyst in mergers and acquisitions group at Wasserstein Perella & Co., an investment banking firm. Ms. Ramasastry currently serves on the board of directors for Vir Biotechnology Inc., Akouos, Inc., Glenmark Pharmaceuticals Ltd., and Sangamo Therapeutics, Inc., and is also a health innovator fellow of the Aspen Institute and a member of the Aspen Global Leadership Network. Ms. Ramasastry holds a B.A. in economics and an M.S. in management science and engineering from Stanford University, as well as an M. Phil. in management studies from the University of Cambridge.